Non Hodgkin Lymphoma (NHL) Market 2023 - By Size, Industry Share, Growth Trends And Global Forecast 2032

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company's Non Hodgkin Lymphoma (NHL) Global Market Report 2023 identifies high prevalence of non-Hodgkin lymphoma as the major driver for the Non Hodgkin Lymphoma (NHL) market's growth in the forecast period. It is a cancer that develops in the lymphatic system, which is part of your immune system. The prevalence of non-Hodgkin lymphoma refers to the number of individuals in a population who are currently diagnosed with or living with the condition at a specific time. Non-Hodgkin lymphoma treatment helps improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells.

The global non Hodgkin lymphoma market size is expected to grow from $8.51 billion in 2022 to $9.34 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global non Hodgkin lymphoma market size is expected to reach $12.97 billion in 2027 at a CAGR of 8.6%.

Download Free Sample Of Non Hodgkin Lymphoma (NHL) Market Report - https://www.thebusinessresearchcompany.com/sample_request?id=10676&type=smp

Major competitors in the Non Hodgkin Lymphoma (NHL) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co., Eli Lilly and Co., Novartis AG.

A key trend in the Non Hodgkin Lymphoma (NHL) market includes advancement in drug innovations. Companies operating in the non-Hodgkin market are focused on innovating new products to sustain their position in the market. For instance, in December 2022, Genentech Inc., a US-based biotechnology company, received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody is a new class of fixed-duration cancer treatment immunotherapy, and it is a readily available and off-the-shelf treatment options patients are not needed to wait to receive this immunotherapy treatment. The FDA approval is based on positive results from the Lunsumio Phase II GO29781 research in persons with extensively pretreated FL, particularly those at high risk of illness progression or unresponsive to prior treatments.

Read More On The Global Non Hodgkin Lymphoma (NHL) Market Report Here:
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

The Non Hodgkin Lymphoma (NHL) market is segmented -

• By Type: B-Cell Lymphoma, T-Cell Lymphoma
• By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
• By Route of Administration: Oral, Parenteral, Other Routes of Administration
• By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
• By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the Non Hodgkin Lymphoma (NHL) market.

The Business Research Company's "Global Non Hodgkin Lymphoma (NHL) Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Non Hodgkin Lymphoma (NHL) Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10676

The Table Of Content For The Non Hodgkin Lymphoma (NHL) Market Include:

1. Executive Summary
2. Non Hodgkin Lymphoma (NHL) Market Characteristics
3. Non Hodgkin Lymphoma (NHL) Market Trends And Strategies
4. Non Hodgkin Lymphoma (NHL) Market - Macro Economic Scenario
5. Non Hodgkin Lymphoma (NHL) Market Size And Growth
………………………………………
26. Africa Non Hodgkin Lymphoma (NHL) Market
27. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market
29. Non Hodgkin Lymphoma (NHL) Market Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.